Cephalon says expenses jumped 30% in Q1

Cephalon reported that selling, general and administrative expenses jumped 30% in the first quarter to $199 million on DTC for narcolepsy drug Provigil (modafinil) and the launch of cancer drug Treanda (bendamustine hydrochloride).
You must be a registered member of MMM to post a comment.

Next Article in Pharmaceutical